Pathophysiological mechanisms of vascular calcification in end-stage renal disease

被引:235
作者
Davies, MR [1 ]
Hruska, KA [1 ]
机构
[1] Barnes Jewish Hosp, Div Renal, St Louis, MO USA
关键词
medial vascular calcification; osteoblast-like cell; renal osteodystrophy; hyperparathyroidism; left ventricular hypertrophy; mineral deposition; atheromatous plaque;
D O I
10.1046/j.1523-1755.2001.060002472.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Vascular calcification has been clearly defined as a risk factor for cardiovascular mortality in the general population and is highly prevalent in end-stage renal disease (ESRD). where it is associated with a number of markers of increased mortality such as left ventricular hypertrophy. The pattern of calcification in ESRD is characterized by mineral deposition in the tunica media, in contrast to non-ESRD populations, where calcification of atheromatous plaque predominates. This difference may have important clinical implications. The pathophysiological mechanisms underlying. both types of vascular calcification remain to be clarified: however, current evidence suggests that they are active processes rather than passive mineral precipitation, and the presence in the vasculature of cells expressing an osteoblastic phenotype may be of central importance. In ESRD, the presence of secondary and tertiary hyperparathyroidism, disordered calcium and phosphate homeostasis, and the use of vitamin D- and calcium based treatments in its therapy may all contribute to vascular calcification. These issues and the impact on other current and future therapies have great importance for clinical nephrology, and a better understanding of vascular calcification through a focused research effort is essential.
引用
收藏
页码:472 / 479
页数:8
相关论文
共 94 条
[1]  
Balica M, 1997, CIRCULATION, V95, P1954
[2]   A case control study of proximal calciphylaxis [J].
Bleyer, AJ ;
Choi, M ;
Igwemezie, B ;
de la Torre, E ;
White, WL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (03) :376-383
[3]   Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management [J].
Block, GA ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) :1226-1237
[4]   BONE MORPHOGENETIC PROTEIN EXPRESSION IN HUMAN ATHEROSCLEROTIC LESIONS [J].
BOSTROM, K ;
WATSON, KE ;
HORN, S ;
WORTHAM, C ;
HERMAN, IM ;
DEMER, LL .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (04) :1800-1809
[5]   ATHEROSCLEROTIC CALCIFICATION - RELATION TO DEVELOPMENTAL OSTEOGENESIS [J].
BOSTROM, K ;
WATSON, KE ;
STANFORD, WP ;
DEMER, LL .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (06) :B88-B91
[6]  
Boström KI, 2000, Z KARDIOL, V89, P69
[7]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[8]   ACCELERATED ATHEROSCLEROSIS IN CHRONIC-DIALYSIS PATIENTS - ANOTHER LOOK [J].
BURKE, JF ;
FRANCOS, GC ;
MOORE, LL ;
CHO, SY ;
LASKER, N .
NEPHRON, 1978, 21 (04) :181-185
[9]  
Campbell GR, 2000, Z KARDIOL, V89, P54
[10]   Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase [J].
Chellaiah, M ;
Hruska, K .
MOLECULAR BIOLOGY OF THE CELL, 1996, 7 (05) :743-753